Citations (58)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Xin Sun, Shan Xu, Zunhua Yang, Pengwu Zheng & Wufu Zhu. (2021) Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: a patent review (2014-present). Expert Opinion on Therapeutic Patents 31:3, pages 223-238.
Read now
Read now
Robert Musiol. (2017) An overview of quinoline as a privileged scaffold in cancer drug discovery. Expert Opinion on Drug Discovery 12:6, pages 583-597.
Read now
Read now
Katharina Feldinger & Anthony Kong. (2015) Profile of neratinib and its potential in the treatment of breast cancer. Breast Cancer: Targets and Therapy 7, pages 147-162.
Read now
Read now
Elena Geuna, Andrea Milani, Stefania Redana, Valentina Rossi, Giorgio Valabrega, Massimo Aglietta & Filippo Montemurro. (2011) Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity?. Expert Opinion on Pharmacotherapy 12:4, pages 549-565.
Read now
Read now
Articles from other publishers (54)
Arabinda Ghosh, Debanjana Ghosh, Nobendu Mukerjee, Swastika Maitra, Padmashree Das, Abhijit Dey, Souty M.Z. Sharkawi, Georgios D. Zouganelis, Athanasios Alexiou, Somdatta Yashwant Chaudhari, Ritika Sharma, Sonali Arun Waghmare, Marios Papadakis & Gaber El-Saber Batiha. (2024) The Efficient Activity of Glabridin and its Derivatives Against EGFRmediated
Inhibition of Breast Cancer. Current Medicinal Chemistry 31:5, pages 573-594.
Crossref
Crossref
Sarina A. Piha-Paul, Chieh Tseng, Hai T. Tran, Meng Gao, Daniel D. Karp, Vivek Subbiah, Apostolia Maria Tsimberidou, Jitesh D. Kawedia, Siqing Fu, Shubham Pant, Timothy A. Yap, Van K. Morris, Bryan K. Kee, Mariela Blum Murphy, JoAnn Lim & Funda Meric-Bernstam. (2023) A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation. Cancer Chemotherapy and Pharmacology 92:2, pages 107-118.
Crossref
Crossref
Sabrina Ninck, Vivek Halder, Jan H. Krahn, Daniela Beisser, Sarah Resch, Isobel DoddsRené Scholtysik, Jenny Bormann, Leonard Sewald, Mainak D. Gupta, Geronimo Heilmann, Deepak D. Bhandari, Kyoko MorimotoPierre BuscaillBettina Hause, Renier A. L. van der HoornFarnusch Kaschani & Markus Kaiser. (2023)
Chemoproteomics Reveals the Pan-HER Kinase Inhibitor Neratinib To Target an
Arabidopsis
Epoxide Hydrolase Related to Phytohormone Signaling
. ACS Chemical Biology 18:5, pages 1076-1088.
Crossref
Crossref
Abdelmoula El Abbouchi, Nabil El Brahmi, Marie-Aude Hiebel, Hamza Ghammaz, Elmostafa El Fahime, Jérôme Bignon, Gérald Guillaumet, Franck Suzenet & Saïd El Kazzouli. (2023) Improvement of the Chemical Reactivity of Michael Acceptor of Ethacrynic Acid Correlates with Antiproliferative Activities. Molecules 28:2, pages 910.
Crossref
Crossref
Yingjie Chang, Xuben Hou & Hao Fang. 2023. Privileged Scaffolds in Drug Discovery. Privileged Scaffolds in Drug Discovery
163
198
.
Syeda Abida Ejaz, Mubashir Aziz, Pervez Rashid Birmani, Bshra A. Alsfouk, F. F. Alharbi, Muhammad Sajjad Bilal, Sidra Hassan, Haruna Isiyaku Umar & Muawya Elhadi. (2022) In Silico Prospects and Therapeutic Applications of Ouabagenin and Hydroxylated Corticosteroid Analogues in the Treatment of Lung Cancer. Applied Biochemistry and Biotechnology 194:12, pages 6106-6125.
Crossref
Crossref
Timothy A. Dinh, Alan F. Utria, Kevin C. Barry, Rosanna Ma, Ghassan K. Abou-Alfa, John D. Gordan, Elizabeth M. Jaffee, John D. Scott, Jessica Zucman-Rossi, Allison F. O’Neill, Mark E. Furth & Praveen Sethupathy. (2022) A framework for fibrolamellar carcinoma research and clinical trials. Nature Reviews Gastroenterology & Hepatology 19:5, pages 328-342.
Crossref
Crossref
Stephanie N. Shishido, Rahul Masson, Liya Xu, Lisa Welter, Rishvanth Kaliappan Prabakar, Anishka D’ Souza, Darcy Spicer, Irene Kang, Priya Jayachandran, James Hicks, Janice Lu & Peter Kuhn. (2022) Disease characterization in liquid biopsy from HER2-mutated, non-amplified metastatic breast cancer patients treated with neratinib. npj Breast Cancer 8:1.
Crossref
Crossref
Paul Dent. 2022. Comprehensive Pharmacology. Comprehensive Pharmacology
250
261
.
Fei Wang, Yulian Ding, Xiujuan Lei, Bo Liao & Fang-Xiang Wu. (2021) Human Protein Complex-Based Drug Signatures for Personalized Cancer Medicine. IEEE Journal of Biomedical and Health Informatics 25:11, pages 4079-4088.
Crossref
Crossref
Xi Wang, Yuanxun Wang, Xuemin Li, Zhenyang Yu, Chun Song & Yunfei Du. (2021) Nitrile-containing pharmaceuticals: target, mechanism of action, and their SAR studies. RSC Medicinal Chemistry 12:10, pages 1650-1671.
Crossref
Crossref
Paul Dent, Andrew Poklepovic, Laurence Booth & John F. Hancock. (2021) The development of multi-kinase inhibitors as pancreatic cancer therapeutics. Anti-Cancer Drugs 32:8, pages 779-785.
Crossref
Crossref
Paul Dent, Laurence Booth, Andrew Poklepovic, Daniel Von Hoff, Jennifer Martinez, Yong Zhou & John F. Hancock. (2021) Osimertinib-resistant NSCLC cells activate ERBB2 and YAP/TAZ and are killed by neratinib. Biochemical Pharmacology 190, pages 114642.
Crossref
Crossref
David E. Heppner & Michael J. Eck. (2021)
A structural perspective on targeting the
RTK
/Ras/
MAP
kinase pathway in cancer
. Protein Science 30:8, pages 1535-1553.
Crossref
Crossref
Thidarath Rattanaburee, Tanotnon Tanawattanasuntorn, Tienthong Thongpanchang, Varomyalin Tipmanee & Potchanapond Graidist. (2021) Trans-(−)-Kusunokinin: A Potential Anticancer Lignan Compound against HER2 in Breast Cancer Cell Lines?. Molecules 26:15, pages 4537.
Crossref
Crossref
Somayyeh Heydari, Davood Habibi, Ali Reza Faraji, Hassan keypour & Masoumeh Mahmoudabadi. (2021) An overview on the progress and development on the palladium catalyzed direct cyanation. Inorganica Chimica Acta 514, pages 119956.
Crossref
Crossref
Paul Dent. 2021. Reference Module in Biomedical Sciences. Reference Module in Biomedical Sciences.
Yong Joo Park, Hyoung-Tae An, Jong-Sung Park, Ogyi Park, Alexander J. Duh, Kwangmeyung Kim, Kyu Hyuck Chung, Kang Choon Lee, Yumin Oh & Seulki Lee. (2020) Tyrosine kinase inhibitor neratinib attenuates liver fibrosis by targeting activated hepatic stellate cells. Scientific Reports 10:1.
Crossref
Crossref
Justus M. Huelse, Diana M. Fridlyand, Shelton Earp, Deborah DeRyckere & Douglas K. Graham. (2020) MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system. Pharmacology & Therapeutics 213, pages 107577.
Crossref
Crossref
Omid Tavassoly, Takashi Sato & Iman Tavassoly. (2020) Inhibition of Brain Epidermal Growth Factor Receptor Activation: A Novel Target in Neurodegenerative Diseases and Brain Injuries. Molecular Pharmacology 98:1, pages 13-22.
Crossref
Crossref
Yanlong Yin, Xiao Yuan, Huile Gao & Qian Yang. (2020) Nanoformulations of small molecule protein tyrosine kinases inhibitors potentiate targeted cancer therapy. International Journal of Pharmaceutics 573, pages 118785.
Crossref
Crossref
Amaia Eleonora Maennling, Mehmet Kemal Tur, Marcus Niebert, Torsten Klockenbring, Felix Zeppernick, Stefan Gattenlöhner, Ivo Meinhold-Heerlein & Ahmad Fawzi Hussain. (2019) Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials. Cancers 11:12, pages 1826.
Crossref
Crossref
Amin Ardestani, Sijia Li, Karthika Annamalai, Blaz Lupse, Shirin Geravandi, Aleksandra Dobrowolski, Shan Yu, Siying Zhu, Tyler D. Baguley, Murali Surakattula, Janina Oetjen, Lena Hauberg-Lotte, Raquel Herranz, Sushil Awal, Delsi Altenhofen, Van Nguyen-Tran, Sean Joseph, Peter G. Schultz, Arnab K. Chatterjee, Nikki Rogers, Matthew S. Tremblay, Weijun Shen & Kathrin Maedler. (2019) Neratinib protects pancreatic beta cells in diabetes. Nature Communications 10:1.
Crossref
Crossref
Maitreyee K. Jathal, Thomas M. Steele, Salma Siddiqui, Benjamin A. Mooso, Leandro S. D’Abronzo, Christiana M. Drake, Young E. Whang & Paramita M. Ghosh. (2019) Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase. British Journal of Cancer 121:3, pages 237-248.
Crossref
Crossref
Bingbing Zhao, Zhen Xiao, Jianguo Qi, Rong Luo, Zhou Lan, Yanzhuo Zhang, Xiaohan Hu, Qidong Tang, Pengwu Zheng, Shan Xu & Wufu Zhu. (2019) Design, synthesis and biological evaluation of AZD9291 derivatives as selective and potent EGFRL858R/T790M inhibitors. European Journal of Medicinal Chemistry 163, pages 367-380.
Crossref
Crossref
Daniel M. Foulkes, Dominic P. ByrneWayland Yeung, Safal Shrestha, Fiona P. BaileySamantha FerriesClaire E. Eyers, Karen Keeshan, Carrow Wells, David H. Drewry, William J. Zuercher, Natarajan KannanPatrick A. Eyers. (2018) Covalent inhibitors of EGFR family protein kinases induce degradation of human Tribbles 2 (TRIB2) pseudokinase in cancer cells. Science Signaling 11:549.
Crossref
Crossref
Annaram Thirupathi, Manojkumar Janni & Saravanan Peruncheralathan. (2018) Copper Catalyzed Intramolecular N-Arylation of Ketene Aminals at Room Temperature: Synthesis of 2-Amino-3-cyanoindoles. The Journal of Organic Chemistry 83:15, pages 8668-8678.
Crossref
Crossref
Tanveer A. Wani, Ahmed H. Bakheit, M. A. Abounassif & Seema Zargar. (2018) Study of Interactions of an Anticancer Drug Neratinib With Bovine Serum Albumin: Spectroscopic and Molecular Docking Approach. Frontiers in Chemistry 6.
Crossref
Crossref
Xin Li, Changyong Yang, Hong Wan, Ge Zhang, Jun Feng, Lei Zhang, Xiaoyan Chen, Dafang Zhong, Liguang Lou, Weikang Tao & Lianshan Zhang. (2017) Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer. European Journal of Pharmaceutical Sciences 110, pages 51-61.
Crossref
Crossref
Karl R. Sorenson, Guilherme Piovezani Ramos, Jose Caetano Villasboas Bisneto & Katharine Price. (2017) Targeted Approaches Applied to Uncommon Diseases: A Case of Salivary Duct Carcinoma Metastatic to the Brain Treated with the Multikinase Inhibitor Neratinib. Case Reports in Oncology 10:2, pages 726-731.
Crossref
Crossref
Susan Breslin, Michelle C Lowry & Lorraine O'Driscoll. (2017) Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4. British Journal of Cancer 116:5, pages 620-625.
Crossref
Crossref
Su-Wei Xu, Betty Yuen Kwan Law, Simon Wing Fai Mok, Elaine Lai Han Leung, Xing Xing Fan, Paolo Saul Coghi, Wu Zeng, Chung-Hang Leung, Dik-Lung Ma, Liang Liu & Vincent Kam Wai Wong. (2016) Autophagic degradation of epidermal growth factor receptor in gefitinib-resistant lung cancer by celastrol. International Journal of Oncology 49:4, pages 1576-1588.
Crossref
Crossref
Chun-Yu Liu, Ming-Hung Hu, Chia-Jung Hsu, Chun-Teng Huang, Duen-Shian Wang, Wen-Chun Tsai, Yi-Ting Chen, Chia-Han Lee, Pei-Yi Chu, Chia-Chi Hsu, Ming-Huang Chen, Chung-Wai Shiau, Ling-Ming Tseng & Kuen-Feng Chen. (2016) Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells. Oncotarget 7:8, pages 9135-9149.
Crossref
Crossref
Aarif Ahsan. 2016. Lung Cancer and Personalized Medicine. Lung Cancer and Personalized Medicine
137
153
.
Jennifer L. Baker, Richard B. Schwab, Anne M. Wallace & Lisa Madlensky. (2015) Breast Cancer in a RAD51D Mutation Carrier: Case Report and Review of the Literature. Clinical Breast Cancer 15:1, pages e71-e75.
Crossref
Crossref
Chaitanya R. Churi, Rachna Shroff, Ying Wang, Asif Rashid, HyunSeon C. Kang, Jacqueline Weatherly, Mingxin Zuo, Ralph Zinner, David Hong, Funda Meric-Bernstam, Filip Janku, Christopher H. Crane, Lopa Mishra, Jean-Nicholas Vauthey, Robert A. Wolff, Gordon Mills & Milind Javle. (2014) Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications. PLoS ONE 9:12, pages e115383.
Crossref
Crossref
Filippo Montemurro & Maurizio Scaltriti. (2014) Biomarkers of drugs targeting HER-family signalling in cancer. The Journal of Pathology 232:2, pages 219-229.
Crossref
Crossref
Monic Roengvoraphoj, Gregory J. Tsongalis, Konstantin H. Dragnev & James R. Rigas. (2013) Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: Focus on epidermal growth factor receptor mutation testing and mutation-positive patients. Cancer Treatment Reviews 39:8, pages 839-850.
Crossref
Crossref
Pia Bükmann Larsen, Iben Kümler & Dorte Lisbet Nielsen. (2013) A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer. Cancer Treatment Reviews 39:7, pages 720-727.
Crossref
Crossref
Alexandra Canonici, Merel Gijsen, Maeve Mullooly, Ruth Bennett, Noujoude Bouguern, Kasper Pedersen, Neil A O’Brien, Ioannis Roxanis, Ji-Liang Li, Esther Bridge, Richard Finn, Dennis Slamon, Patricia McGowan, Michael J. Duffy, Norma O’Donovan, John Crown & Anthony Kong. (2013) Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. Oncotarget 4:10, pages 1592-1605.
Crossref
Crossref
Huan-ling Wang, Khalil G. Ghanem, Peng Wang, Shuang Yang & Tai-sheng Li. (2013) Listeriosis at a Tertiary Care Hospital in Beijing, China: High Prevalence of Nonclustered Healthcare-Associated Cases Among Adult Patients. Clinical Infectious Diseases 56:5, pages 666-676.
Crossref
Crossref
M. Fralick, J.F. Hilton, N. Bouganim, M. Clemons & E. Amir. (2012) Dual Blockade of HER2 — Twice as Good or Twice as Toxic?. Clinical Oncology 24:9, pages 593-603.
Crossref
Crossref
Dimitrios Zardavas, Lina Pugliano, Felipe Ades, Ivana Bozovic-Spasojevic, Marta Capelan & Evandro de Azambuja. (2012) Targeted treatments of HER2-positive metastatic breast cancer: trastuzumab and beyond. Breast Cancer Management 1:3, pages 217-233.
Crossref
Crossref
Ondrej Kalous, Dylan Conklin, Amrita J. Desai, Neil A. O'Brien, Charles Ginther, Lee Anderson, David J. Cohen, Carolyn D. Britten, Ian Taylor, James G. Christensen, Dennis J. Slamon & Richard S. Finn. (2012) Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib. Molecular Cancer Therapeutics 11:9, pages 1978-1987.
Crossref
Crossref
Michal Bista, David Smithson, Aleksandra Pecak, Gabriella Salinas, Katarzyna Pustelny, Jaeki Min, Artur Pirog, Kristin Finch, Michal Zdzalik, Brett Waddell, Benedykt Wladyka, Sylwia Kedracka-Krok, Michael A. Dyer, Grzegorz Dubin & R. Kiplin Guy. (2012) On the Mechanism of Action of SJ-172550 in Inhibiting the Interaction of MDM4 and p53. PLoS ONE 7:6, pages e37518.
Crossref
Crossref
Sara López-Tarruella, Yolanda Jerez, Iván Márquez-Rodas & Miguel Martín. (2012) Neratinib (HKI-272) in the treatment of breast cancer. Future Oncology 8:6, pages 671-681.
Crossref
Crossref
Eunice Kwak. (2011) The Role of Irreversible HER Family Inhibition in the Treatment of Patients with Non-Small Cell Lung Cancer. The Oncologist 16:11, pages 1498-1507.
Crossref
Crossref
Stephan Macher-Goeppinger, Roland Penzel, Wilfried Roth, Hendrik Dienemann, Michael Thomas, Philipp Albert Schnabel, Peter Schirmacher & Hendrik Bläker. (2011) Expression and mutation analysis of EGFR, c-KIT, and β-catenin in pulmonary blastoma. Journal of Clinical Pathology 64:4, pages 349-353.
Crossref
Crossref
Lingxiang Liu, Xiaoyan Shao, Wen Gao, Jianling Bai, Rongsheng Wang, Puwen Huang, Yongmei Yin, Ping Liu & Yongqian Shu. (2010) The Role of Human Epidermal Growth Factor Receptor 2 as a Prognostic Factor in Lung Cancer: A Meta-Analysis of Published Data. Journal of Thoracic Oncology 5:12, pages 1922-1932.
Crossref
Crossref
Fraser F. Fleming, Lihua Yao, P. C. Ravikumar, Lee Funk & Brian C. Shook. (2010) Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore. Journal of Medicinal Chemistry 53:22, pages 7902-7917.
Crossref
Crossref
Georgios Giamas, Yik L. Man, Heidrun Hirner, Joachim Bischof, Klaus Kramer, Kalimullah Khan, Sharmeen S. Lavina Ahmed, Justin Stebbing & Uwe Knippschild. (2010) Kinases as targets in the treatment of solid tumors. Cellular Signalling 22:7, pages 984-1002.
Crossref
Crossref
Chau DangNancy LinBeverly MoySteven ComeSteven SugarmanPatrick MorrisAlyson AbbruzziCarol ChenRichard SteingartSujata PatilLarry NortonEric WinerClifford Hudis. (2010)
Dose-Dense Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel With Trastuzumab and Lapatinib in HER2/
neu
–Overexpressed/Amplified Breast Cancer Is Not Feasible Because of Excessive Diarrhea
. Journal of Clinical Oncology 28:18, pages 2982-2988.
Crossref
Crossref
Per E. Lønning. (2010) Molecular basis for therapy resistance. Molecular Oncology 4:3, pages 284-300.
Crossref
Crossref
Lee S. Rosen, Helen Louise Ashurst & Linnea Chap. (2010) Targeting Signal Transduction Pathways in Metastatic Breast Cancer: A Comprehensive Review. The Oncologist 15:3, pages 216-235.
Crossref
Crossref